What is Chardan Capital’s Forecast for UBX FY2024 Earnings?

Posted by ABMN Staff on Jan 16th, 2025

Unity Biotechnology, Inc. (NASDAQ:UBX – Free Report) – Analysts at Chardan Capital issued their FY2024 EPS estimates for Unity Biotechnology in a note issued to investors on Sunday, January 12th. Chardan Capital analyst D. Gataulin anticipates that the company will earn ($1.41) per share for the year. Chardan Capital currently has a “Buy” rating and a $6.00 target price on the stock. The consensus estimate for Unity Biotechnology’s current full-year earnings is ($1.49) per share. Chardan Capital also issued estimates for Unity Biotechnology’s FY2025 earnings at ($0.74) EPS.

Unity Biotechnology Price Performance

Shares of UBX opened at $1.69 on Wednesday. Unity Biotechnology has a one year low of $0.94 and a one year high of $2.02. The company has a 50-day simple moving average of $1.20 and a two-hundred day simple moving average of $1.36. The firm has a market capitalization of $28.48 million, a PE ratio of -1.29 and a beta of 0.80.

Unity Biotechnology (NASDAQ:UBX – Get Free Report) last issued its quarterly earnings data on Monday, November 4th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.02.

Hedge Funds Weigh In On Unity Biotechnology

A hedge fund recently bought a new stake in Unity Biotechnology stock. Ballentine Partners LLC bought a new stake in shares of Unity Biotechnology, Inc. (NASDAQ:UBX – Free Report) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 57,046 shares of the company’s stock, valued at approximately $84,000. Ballentine Partners LLC owned about 0.34% of Unity Biotechnology as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 29.49% of the company’s stock.

About Unity Biotechnology

(Get Free Report)

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.